Note 6 - Research and Development Rebate Receivable	6 Months Ended
Jun. 30, 2022
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal a qualified program and related expenditures could be disqualified, and the respective R&D rebates could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received from the Australian government. During the three and six months ended June 30, 2022, the Company incurred qualified R&D expenses in Australia of $607 and $930, respectively. Qualified R&D expenses incurred by the Company were $275 and $546 during the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022 and June 30, 2021, the Company collected R&D cash rebates of $629 and $0, respectively. At June 30, 2022 and December 31, 2021, we had a total research and development rebate receivable of $900 and $1,072, respectively. We record the R&D rebate credit in the period when we incur the associated R&D cost. As such, the rebate reduced the Research and Development expense line item on the Condensed Consolidated Statements of Operations by $264 and $404 for the three and six months ended June 30, 2022 and $109 and $216 for the same periods in 2021, respectively. The Company had realized losses on foreign currency exchange, related to the research and development rebate receivable balance, during the three and six months ended June 30, 2022 of $85 and $114, respectively, and $33 and $38 for the same periods in 2021, respectively. Foreign currency exchange gains and losses are included in Other expense, net in the Condensed Consolidated Statements of Operations.

Note 6 - Research and Development Rebate Receivable

6 Months Ended

Jun. 30, 2022

Research and Development Tax Rebate Receivable [Text Block]

NOTE 6: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE

On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal a qualified program and related expenditures could be disqualified, and the respective R&D rebates could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received from the Australian government.

During the three and six months ended June 30, 2022, the Company incurred qualified R&D expenses in Australia of $607 and $930, respectively. Qualified R&D expenses incurred by the Company were $275 and $546 during the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022 and June 30, 2021, the Company collected R&D cash rebates of $629 and $0, respectively. At June 30, 2022 and December 31, 2021, we had a total research and development rebate receivable of $900 and $1,072, respectively. We record the R&D rebate credit in the period when we incur the associated R&D cost. As such, the rebate reduced the Research and Development expense line item on the Condensed Consolidated Statements of Operations by $264 and $404 for the three and six months ended June 30, 2022 and $109 and $216 for the same periods in 2021, respectively.

The Company had realized losses on foreign currency exchange, related to the research and development rebate receivable balance, during the three and six months ended June 30, 2022 of $85 and $114, respectively, and $33 and $38 for the same periods in 2021, respectively. Foreign currency exchange gains and losses are included in Other expense, net in the Condensed Consolidated Statements of Operations.